MAPT and Alzheimer disease: The CSF biomarkers, including Aβ1‐42, total tau (t‐tau), and phosphorylated tau (p‐tau), have been shown good sensitivity and specificity for differentiating AD patients from healthy controls29, 30 and succeed as a diagnosis for AD.